What it isInhaled loxapine (ADASUVE, 2012) — single-use Staccato inhaler, IV-like speed without a needle for acute agitation; REMS: bronchospasm risk, contraindicated in asthma/COPD.
Why this oneSame molecule and receptor pharmacology as the parent card — the formulation (and its label) is the difference.
What limits itClass warnings of the parent molecule apply unchanged.
BOXED WARNING Bronchospasm (potential respiratory distress/arrest), available only via ADASUVE REMS; increased mortality in elderly with dementia-related psychosis.
FDA dosing
Population
Start
Target
Max
Acute agitation associated with schizophrenia or bipolar I disorder
Adults
10 mg by oral inhalation, single dose
10 mg per 24 h (single dose only)
Renal Undefined
Hepatic Undefined
Only a single dose within any 24-hour period
Instructions
Administer only by a healthcare professional in a certified healthcare setting
Screen for pulmonary disease and assess respiratory status (chest auscultation) before dosing
Monitor for bronchospasm for at least 1 hour after administration
Single-use inhaler; discard after one use
Available strengths
powder 10 mg
cap 5, 10, 25, 50 mg
Contraindications
Current diagnosis/history of asthma, COPD, or other lung disease associated with bronchospasm
Acute respiratory signs/symptoms (e.g., wheezing)
Current use of medications to treat airways disease (asthma/COPD)
History of bronchospasm following ADASUVE treatment
Pregnancy Third-trimester exposure risks extrapyramidal/withdrawal symptoms in neonates; data insufficient for birth-defect risk.
Lactation No human data; consider benefits of breastfeeding vs. maternal need and potential infant effects.
Cost
Loxapine inhaled (ADASUVE)
Strength
#/mo
generic $/unit
CostPlus
10 mg
powder
per unit
not offered
NADAC is a voluntary CMS survey of what retail community pharmacies pay for the drugs they stock. Loxapine inhaled is dispensed outside retail pharmacies, so it rarely appears on surveyed invoices.